Vertex Pharmaceuticals (VRTX) Expected to Post Earnings on Monday

Vertex Pharmaceuticals (NASDAQ:VRTX) is expected to issue its Q3 2026 results after the market closes on Monday, November 2nd. Analysts expect Vertex Pharmaceuticals to post earnings of $4.80 per share and revenue of $3.42 billion for the quarter. Parties can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Monday, November 2, 2026 at 4:30 PM ET.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Monday, August 3rd. The pharmaceutical company reported $4.73 EPS for the quarter, missing analysts’ consensus estimates of $4.74 by ($0.01). Vertex Pharmaceuticals had a net margin of 35.00% and a return on equity of 23.09%. The business had revenue of $3.33 billion for the quarter, compared to analysts’ expectations of $3.23 billion. During the same period in the prior year, the company posted $4.52 earnings per share. The firm’s quarterly revenue was up 12.5% on a year-over-year basis. On average, analysts expect Vertex Pharmaceuticals to post $16.74 EPS for the current fiscal year and $18.44 EPS for the next fiscal year.

Vertex Pharmaceuticals Stock Performance

VRTX opened at $523.93 on Monday. Vertex Pharmaceuticals has a 1-year low of $403.16 and a 1-year high of $560.25. The company has a market capitalization of $132.97 billion, a PE ratio of 30.50, a PEG ratio of 2.51 and a beta of 0.28. The firm’s 50 day simple moving average is $523.52 and its two-hundred day simple moving average is $483.59.

Analyst Ratings Changes

VRTX has been the subject of a number of recent research reports. Evercore boosted their price objective on shares of Vertex Pharmaceuticals from $535.00 to $600.00 and gave the company an “outperform” rating in a research report on Wednesday, September 2nd. Barclays raised their target price on Vertex Pharmaceuticals from $615.00 to $617.00 and gave the stock an “overweight” rating in a report on Wednesday, August 5th. Wall Street Zen raised Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, October 17th. Leerink Partners initiated coverage on Vertex Pharmaceuticals in a research report on Monday, September 21st. They set an “outperform” rating and a $594.00 target price on the stock. Finally, Weiss Ratings raised Vertex Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a report on Friday, October 16th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $579.81.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.